–  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases –  Lead target and indication to be announced MY 2025 –  Cash balance of $185.2 million expected to fund operations into 2H 2027 Get the latest news delivered to your inbox Sign up for The Manila Times